Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Green

Endocrinology, Diabetes & Metabolism Durham, NC Medical Doctor

NPI 1770674517 CMS profile 812252

Duke University Medical Center/ Div Of Endocrinology, Dumc Box 3222, Baker House Room 280, Durham, NC 27710

Open in the dashboard

General payments

$438,605

421 records reported · program years 2019–2025

Research payments

$8,562

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Green of Durham, NC is reported in the CMS Open Payments database as having received $438,605 across 421 general payments and $8,562 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82,888 86
2024 General $93,844 90
2024 Research $550 1
2023 General $97,139 74
2023 Research $3,025 3
2022 General $64,928 63
2021 General $26,530 27
2020 General $22,890 14
2020 Research $4,400 2
2019 General $50,386 67
2019 Research $587 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Green
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Jennifer Green were reported at $82,888. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Jennifer Green Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $50,386 $494 $123–$2,253 $163
2020 $22,890 $335 $85–$1,841 $114
2021 $26,530 $398 $88–$1,981 $132
2022 $64,928 $364 $88–$1,568 $149
2023 $97,139 $420 $113–$1,614 $160
2024 $93,844 $440 $121–$1,646 $164
2025 $82,888 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eli Lilly and Company $141,059 130 payments
  2. Boehringer Ingelheim International GmbH $67,736 55 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $67,193 84 payments
  4. Novo Nordisk Inc $57,138 34 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $52,432 47 payments
  6. Vertex Pharmaceuticals Incorporated $25,325 24 payments
  7. Novo Nordisk AS $7,279 5 payments
  8. Corcept Therapeutics $6,133 4 payments
  9. Idorsia Pharmaceuticals US Inc $4,865 1 payment
  10. Lilly USA, LLC $4,413 6 payments
  11. Other $5,032 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $296,696 115 payments
  2. Travel and Lodging $90,179 126 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,785 14 payments
  4. Food and Beverage $8,945 166 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $76,101 91 payments
  2. Kerendia $28,246 33 payments
  3. JARDIANCE Diabetes $10,435 4 payments
  4. Victoza $10,004 5 payments
  5. Korlym $6,133 4 payments
  6. MOUNJARO $5,887 6 payments
  7. Tryvio $4,865 1 payment
  8. JARDIANCE Diabetes $2,100 1 payment
  9. Ozempic $2,000 2 payments
  10. FARXIGA $269 1 payment
  11. Other $558 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $4,400 2 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $3,575 4 payments
  3. E.R. Squibb & Sons, L.L.C. $587 1 payment

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record